Director/PDMR Shareholding

RNS Number : 1420Y

Hikma Pharmaceuticals Plc

16 December 2010

 



Hikma Pharmaceuticals PLC - Share Transactions

LONDON, 16 December 2010: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK), in accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, announces that Mr. Mazen Darwazah, a Director and Person Discharging Managerial Responsibility has undertaken transactions in the Company's Ordinary Shares of 10p each. The transactions took place in London as detailed below.

On 16 December 2010, Mr Darwazah disposed of 291,366 Ordinary Shares of 10p each, representing 0.15 per cent. of the issued share capital of the Company, at an average price of 812.5 pence per Ordinary Share. The primary purpose of this disposal is to fund the establishment of the Samih Darwazah Center for Innovation Management and Entrepreneurship at the American University of Beirut in Lebanon.

The Company was notified of the transaction on 16 December 2010.

Following these transactions Mr. Darwazah holds 695,225 ordinary shares, representing 0.36 per cent. of the issued share capital of the Company.

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC 

Henry Knowles                                                 [phone]

Company Secretary

Susan Ringdal                                                  [phone]

Investor Relations Director

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2009, Hikma achieved revenues of $637 million and profit attributable to shareholders of $78 million.  For news and other information, please visit www.hikma.com.

 

END

 

 

RDSBRBDDUDBBGGL